Login to Your Account


Hiding EGFR-Targeting Antibody Improves Its Safety Profile

By Anette Breindl
Science Editor

Wednesday, October 16, 2013
A team from South San Francisco based Cytomx Therapeutics Inc. reported today that it has developed an EGFR-targeting “probody” that was activated specifically in the tumor microenvironment, allowing its delivery at higher doses than conventional antibodies to both mice and primates. The experiments, Cytomx’ chief scientific officer Henry Lowman told BioWorld Today, showed that “antibodies can be masked and locally activated,” and that in doing so, “safety is really improved.” They were published in the Oct. 17, 2013, issue of Science Translational Medicine.

To continue reading subscribe now to Science News

Learn More about Science News

Already a subscriber? Sign In or Buy now to activate your subscription